In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on ChemoCentryx (CCXI), with a price target of $20. The company’s shares closed yesterday at $11.70.
White wrote:
“We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2018 net cash of $2.58/ share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.9% and a 46.6% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
ChemoCentryx has an analyst consensus of Moderate Buy, with a price target consensus of $16.38.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.08 and a one-year low of $5.42. Currently, ChemoCentryx has an average volume of 231.8K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.
